Held by 1 specialist biotech fund
Signal Note: Deerfield Exit from DXC Technology
This exit is immaterial to biotech fundamentals—DXC is an IT services/infrastructure software provider with no drug pipeline, making Deerfield's healthcare-focused mandate a poor fit regardless of valuation. The exit likely reflects portfolio rebalancing rather than a sector-specific thesis change and does not signal conviction shift within the healthcare space.